To test if the differences in the tumor cells between ERG− and ERG+ patients could potentially drive distinct and common stromal and immune responses, we ran independent GSEA analysis between ERG− and ERG+ tumor cells, CD4 T-cells, and stromal cells and computed the intersection of significantly upregulated gene sets in ERG- patients (FDR q < 0.1, Wilcoxon rank-sum test). The gene discussed is CD4; the disease is neoplasm.